The first case of COVID-19 treated with the complement C3 inhibitor AMY-101.
Aged
Antiviral Agents
/ therapeutic use
Atrial Fibrillation
/ drug therapy
Betacoronavirus
/ drug effects
COVID-19
Complement Activation
/ drug effects
Complement C3
/ antagonists & inhibitors
Complement Inactivating Agents
/ therapeutic use
Coronavirus Infections
/ drug therapy
Humans
Hypercholesterolemia
/ drug therapy
Hypertension
/ drug therapy
Lung
/ drug effects
Male
Pandemics
Peptides, Cyclic
/ therapeutic use
Pneumonia, Viral
/ drug therapy
SARS-CoV-2
Treatment Outcome
Journal
Clinical immunology (Orlando, Fla.)
ISSN: 1521-7035
Titre abrégé: Clin Immunol
Pays: United States
ID NLM: 100883537
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
27
04
2020
accepted:
27
04
2020
pubmed:
4
5
2020
medline:
24
6
2020
entrez:
4
5
2020
Statut:
ppublish
Résumé
Acute respiratory distress syndrome (ARDS) is a devastating clinical manifestation of COVID-19 pneumonia and is mainly based on an immune-driven pathology. Mounting evidence suggests that COVID-19 is fueled by a maladaptive host inflammatory response that involves excessive activation of innate immune pathways. While a "cytokine storm" involving IL-6 and other cytokines has been documented, complement C3 activation has been implicated as an initial effector mechanism that exacerbates lung injury in preclinical models of SARS-CoV infection. C3-targeted intervention may provide broader therapeutic control of complement-mediated inflammatory damage in COVID-19 patients. Herein, we report the clinical course of a patient with severe ARDS due to COVID-19 pneumonia who was safely and successfully treated with the compstatin-based complement C3 inhibitor AMY-101.
Identifiants
pubmed: 32360516
pii: S1521-6616(20)30331-4
doi: 10.1016/j.clim.2020.108450
pmc: PMC7189192
pii:
doi:
Substances chimiques
Antiviral Agents
0
Complement C3
0
Complement Inactivating Agents
0
Peptides, Cyclic
0
compstatin
0
Types de publication
Case Reports
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
108450Subventions
Organisme : NIAID NIH HHS
ID : P01 AI068730
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Références
Emerg Microbes Infect. 2018 Apr 24;7(1):77
pubmed: 29691378
Front Immunol. 2019 Mar 12;10:406
pubmed: 30915073
Eur J Clin Invest. 2015 Apr;45(4):423-40
pubmed: 25678219
J Cell Mol Med. 2015 Nov;19(11):2549-63
pubmed: 26337158
Shock. 2019 Jan;51(1):78-87
pubmed: 29461464
Crit Care Med. 2000 Sep;28(9):3149-54
pubmed: 11008973
Clin Immunol. 2018 Dec;197:96-106
pubmed: 30217791
Crit Care Resusc. 2020 Apr 15;22(2):95-97
pubmed: 32294809
Transl Res. 2020 Jun;220:1-13
pubmed: 32299776
Circulation. 2020 Jun 2;141(22):1739-1741
pubmed: 32271624
Clin Immunol. 2015 Dec;161(2):225-40
pubmed: 26341313
J Med Chem. 2018 Jul 26;61(14):6153-6162
pubmed: 29920096
Nat Rev Immunol. 2020 Jun;20(6):343-344
pubmed: 32327719
N Engl J Med. 2017 Aug 10;377(6):562-572
pubmed: 28792873
mBio. 2018 Oct 9;9(5):
pubmed: 30301856
Clin Immunol. 2016 Oct;171:32-35
pubmed: 27546448
Nat Rev Drug Discov. 2019 Sep;18(9):707-729
pubmed: 31324874
Clin Immunol. 2019 Jan;198:102-105
pubmed: 30472267